Nevirapine Patent Expiration

Nevirapine is Used for managing HIV-1 infection through once-daily administration. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc in its drug Viramune on Jun 21, 1996. Another drug containing Nevirapine is Viramune Xr. 17 different companies have introduced drugs containing Nevirapine.


Nevirapine Patents

Given below is the list of patents protecting Nevirapine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Viramune Xr US8460704 Extended release formulation of nevirapine Mar 12, 2029 Boehringer Ingelheim


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nevirapine's patents.

Given below is the list recent legal activities going on the following patents of Nevirapine.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 21 Sep, 2020 US8460704
Post Issue Communication - Certificate of Correction 05 Feb, 2015 US8460704
Email Notification 13 Sep, 2014 US8460704
Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Allowance 10 Sep, 2014 US8460704
Record a Petition Decision of Granted for Patent Term Adjustment after Allowance 09 Sep, 2014 US8460704
Adjustment of PTA Calculation by PTO 05 Sep, 2014 US8460704
Petition Entered 14 Jun, 2013 US8460704
Recordation of Patent Grant Mailed 11 Jun, 2013 US8460704
Patent Issue Date Used in PTA Calculation 11 Jun, 2013 US8460704
Email Notification 23 May, 2013 US8460704



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Nevirapine Generics

Several generic applications have been filed for Nevirapine. The first generic version for Nevirapine was by Cipla Ltd and was approved on May 22, 2012. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Jan 14, 2019.

Given below is the list of companies who have filed for Nevirapine generic.


1. MYLAN PHARMS INC

Mylan Pharmaceuticals Inc has filed for 1 generic for Nevirapine. Given below are the details of the strengths of this generic introduced by Mylan Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Prescription ORAL AB May 22, 2012


2. CIPLA

Cipla Ltd has filed for 3 different strengths of generic version for Nevirapine. Given below are the details of the strengths of this generic introduced by Cipla.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Prescription ORAL AB May 22, 2012
400MG tablet, extended release Discontinued ORAL N/A Oct 15, 2015
50MG/5ML suspension Prescription ORAL AA Aug 3, 2017


3. MYLAN LABS

Mylan Laboratories Ltd has filed for 1 generic for Nevirapine. Given below are the details of the strengths of this generic introduced by Mylan Labs.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Discontinued ORAL N/A May 22, 2012


4. MYLAN

Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Nevirapine. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
400MG tablet, extended release Prescription ORAL AB Oct 27, 2014
100MG tablet, extended release Discontinued ORAL N/A Nov 9, 2015


5. MACLEODS PHARMS LTD

Macleods Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Nevirapine. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
400MG

(reference standard)

tablet, extended release Prescription ORAL AB Oct 6, 2017
200MG

(reference standard)

tablet Prescription ORAL AB Jan 14, 2019


6. SANDOZ

Sandoz Inc has filed for 1 generic for Nevirapine. Given below are the details of the strengths of this generic introduced by Sandoz.

Strength Dosage Form Availability Application Pathway TE code Launch Date
400MG tablet, extended release Prescription ORAL AB Apr 3, 2014


7. HETERO LABS LTD III

Hetero Labs Ltd Unit Iii has filed for 1 generic for Nevirapine. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Prescription ORAL AB May 22, 2012


8. APOTEX INC

Apotex Inc has filed for 1 generic for Nevirapine. Given below are the details of the strengths of this generic introduced by Apotex Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Discontinued ORAL N/A May 22, 2012


9. STRIDES PHARMA

Strides Pharma Global Pte Ltd has filed for 1 generic for Nevirapine. Given below are the details of the strengths of this generic introduced by Strides Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Prescription ORAL AB May 22, 2012


10. MICRO LABS LTD

Micro Labs Ltd has filed for 1 generic for Nevirapine. Given below are the details of the strengths of this generic introduced by Micro Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Prescription ORAL AB May 22, 2012


11. TECH ORGANIZED

Technology Organized Llc has filed for 3 different strengths of generic version for Nevirapine. Given below are the details of the strengths of this generic introduced by Tech Organized.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Discontinued ORAL N/A May 22, 2012
100MG tablet, extended release Discontinued ORAL N/A Jul 31, 2017
400MG tablet, extended release Discontinued ORAL N/A Jul 31, 2017


12. AUROBINDO PHARMA

Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Nevirapine. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
100MG tablet, extended release Discontinued ORAL N/A Nov 23, 2016
400MG tablet, extended release Discontinued ORAL N/A Feb 28, 2017


13. ALVOGEN

Alvogen Inc has filed for 2 different strengths of generic version for Nevirapine. Given below are the details of the strengths of this generic introduced by Alvogen.

Strength Dosage Form Availability Application Pathway TE code Launch Date
400MG tablet, extended release Discontinued ORAL N/A Jul 10, 2015
100MG tablet, extended release Discontinued ORAL N/A Nov 9, 2015


14. PRINSTON INC

Prinston Pharmaceutical Inc has filed for 1 generic for Nevirapine. Given below are the details of the strengths of this generic introduced by Prinston Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Discontinued ORAL N/A May 22, 2012


15. APOTEX

Apotex Inc has filed for 1 generic for Nevirapine. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
400MG tablet, extended release Discontinued ORAL N/A Apr 3, 2014


16. AUROBINDO

Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Nevirapine. Given below are the details of the strengths of this generic introduced by Aurobindo.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG tablet Prescription ORAL AB May 22, 2012
50MG/5ML

(reference standard)

suspension Prescription ORAL AA May 22, 2012